This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
« Back
Page 1 of 21

Abbvie's Hep C Regimen Approved, Marketing Battle With Gilead Up Next

By Adam Feuerstein

U.S. regulators approved a new hepatitis C therapy from Abbvie, heralding a new era of market competition with Gilead Sciences.

04:16PM 12/19/14

Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators

By Adam Feuerstein

European regulators recommended the approval of Orexigen Therapeutics weight-loss pill on Friday, opening a new commercial market opportunity closed off to the company's competitors.

08:25AM 12/19/14

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

By Adam Feuerstein

One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.

11:20AM 12/16/14

Former Onyx CEO Returns to Biotech to Launch Boston Start Up

By Adam Feuerstein

Tony Coles, the former CEO of Onyx sold to Amgen for $10 billion in late 2013, is launching Yumanity Therapeutics focused on developing drugs for neuro-degenerative diseases.

09:23AM 12/15/14

Array Biopharma Regains Rights to Cancer Drug From Novartis

By Adam Feuerstein

The re-acquisition of binimetinib by Array was expected after Novartis announced in April a business swap with GlaxoSmithKline GSK which included the acquisition of Glaxo's cancer drug business.

04:01PM 12/03/14

Amgen Wins U.S. Approval for Immunotherapy Against Leukemia

By Adam Feuerstein

Wednesday's approval of Blincyto comes more than five months ahead of the expected May 19, 2015 approval decision date.

01:31PM 12/03/14

Puma Forced to Delay Breast Cancer FDA Submission Due to New Safety Data Requirement

By Adam Feuerstein

Puma Biotechnology is pushing back an approval filing for its breast cancer drug neratinib into 2016 -- almost a one year delay.

04:34PM 12/02/14

Future of Exelixis Cancer Drug Dims Further With Second Failed Prostate Cancer Study

By Adam Feuerstein

All too often, promising results from phase II studies don't pan out when larger, confirmatory phase III studies are conducted. That's exactly what happened to Exelixis.

11:37AM 12/01/14

Galena, Shunned by Wall Street, Forced to Seek Pricey Vulture Financing

By Adam Feuerstein

The scandal-ridden Galena, still under active SEC investigation, was unable to muster sufficient interest from institutional investors.

09:39AM 11/24/14

Royalty Pharma's $3.3 Billion Transaction is Bullish for Vertex Pharma

By Adam Feuerstein

The $3.3 billion paid by Royalty Pharma to the Cystic Fibrosis Foundation to acquire royalty rights to Vertex Pharmaceuticals' cystic fibrosis drugs suggests investors are under-estimating peak sales.

01:25PM 11/19/14

« Back
Page 1 of 21

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 18,065.00 +11.29 0.06%
S&P 500 2,092.61 +3.84 0.18%
NASDAQ 4,811.5380 +4.6790 0.10%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs